Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Phase 3UnknownNCT05602090

Beni-Suef University120 enrolled

Overview

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients

To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Poor Ovarian Reserve

Interventions

4 IU of recombinant GH (Somatotropin )DRUG

4 IU of recombinant GH

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: According to Bologna criteria (((at least two )))of the following features must be present: 1. Advanced maternal age (40years). 2. A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation 3. An abnormal ovarian reserve test (ORT) * antral follicle count (AFC)\<7 or * anti-Müllerian hormone (AMH)\<1.1ng/ml. Exclusion Criteria: 1. Any known contraindications to the approved fertility drugs. 2. Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment) 4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity. 6- Basal FSH more than 17 IU. 7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.

Locations (1)

Beni-suef university

Banī Suwayf, Beni Suweif Governorate, Egypt

RECRUITING

Outcomes

Primary Outcomes

pregnancy rate

HCG positive

Time frame: ICSI trial (1month)

Central Contacts

Sara A Salem, MD

CONTACT

01272842226 sara_abdallah100@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.